New findings on COX-2 arthritis drugs
The celebrated arthritis drug Celebrex has demonstrated additional benefits. A new study to assess the overall long- term safety of Celebrex (celecoxib capsules) found that arthritis patients taking four times the recommended osteoarthritis dose of the drug experienced fewer symptomatic gastrointestinal ulcers and ulcer complications than patients taking ibuprofen and diclofenac at their typical daily dose.
The study, funded by Searle and Pfizer Inc, also demonstrated differences on a variety of measures in renal and liver toxicity among those taking Celebrex or the traditional NSAID comparators, two of the world’s most widely prescribed drugs of this kind. Celebrex also showed no increase in thromboembolic or other cardiovascular-related events, even among non-aspirin users.